Coronavirus Update: Pfizer Vaccine Candidates Gain Fast-Track Status
Two mRNA Candidates Selected
Executive Summary
The granting of fast-track status is a clear signal that the US FDA wants to maintain its high standards of drug and vaccine appraisal.
You may also be interested in...
Finance Watch: 2020 Is Four Biopharma IPOs Away From Matching 2019
With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.
Fosun’s IPO Plan For India’s Gland Hits Multiple Targets
With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.
Congressional Democrats Press US FDA For Transparency In Review Of COVID-19 Vaccines
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.